Cybin
CYBN8.2800.00% ( 0.000 )
Cybin (CYBN)
Cybin Inc., a clinical-stage neuropsychiatry company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. It develo...
- Open
- --
- High
- --
- Low
- --
- Prev. Close
- 8.280
- Volume
- 0
- Turnover
- 0
- Avg Price
- --
- Bid/Ask Ratio
- --
- Amplitude
- --
- 52wk High
- 9.120
- Volume Ratio
- 0.00
- Turnover Ratio
- --
Cybin Analyst Rating
View MoreForecast & Rating
Dec 3, 2025Price forecast
--100.00%
Forecast & RatingStrong buy
7analysts
- Strong buy100.00%
- Buy0.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- PUBT · Jun 29 at 07:00 AM
Cybin publishes MD&A for year ended March 31, 2026
- MorningStar · May 26 at 12:50 PM
New Study Conducted at Sheppard Pratt Finds Psilocybin-Assisted Therapy May Reduce Chronic Suicidal Ideation
- Barchart Option · Apr 28 at 02:45 PM
Trump Wants to Give Psychedelics Stocks a Boost. Can This Leading Company Deliver?
- rttnews · Apr 24 at 04:50 PM
FDA Moves To Fast-Track Psychedelic Therapies For Mental Health
- Thehill · Apr 22 at 10:05 PM
Trump’s Rogan-inspired psychedelics order stokes cautious optimism
- ZeroHedge · Apr 22 at 07:37 AM
Psychedelic Stocks Just Went Mainstream
